News summary

Newsletter text

Puli Pharmaceuticals announced that cyclophosphamide bulk drug has been approved for marketing

Puli Pharmaceutical Co., Ltd. recently announced that its subsidiary Anhui Puli Pharmaceutical Co., Ltd. has successfully been awarded by the State Food and Drug AdministrationpokerallinrulesNotice of approval for the marketing application of cyclophosphamide chemical raw material. This approval marks an important progress made by Puli Pharmaceuticals in the field of alkylating agent cytotoxic drugs. As a type of alkylating agent, cyclophosphamide has significant DNA interference properties. It can destroy the functions of DNA and RNA, form cross-bonds with DNA, and thereby inhibit the DNA synthesis process. The approval of this drug has had a positive impact on Puli Pharmaceutical's competitiveness in related drug markets.